Evidence map›Paper›PMID 28596948›Full record

ReviewClinical and translational imaging2017

Standardization of

Kenichi Nakajima, Derk O Verschure, Koichi Okuda, Hein J Verberne

Registry-linked trialAbstract readReview
In one paragraph

Review in Clinical and translational imaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06965621 (An Open-Label, Exploratory, Phase 2 Scintigraphy Study Evaluating 18F mFBG for Imaging Myocardial Sympathetic Innervation in Subjects With Heart Failure and Implantable Cardioverter-Defibrillators), which is not on this map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06965621 phase2recruitingnot on this mapstarted 2025, after this paper: background citation

An Open-Label, Exploratory, Phase 2 Scintigraphy Study Evaluating 18F mFBG for Imaging Myocardial Sympathetic Innervation in Subjects With Heart Failure and Implantable Cardioverter-Defibrillators

TypeinterventionalSponsorInnervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)Ran2025 to 2026Enrolled20ConditionsHeart Failure, Ischemic Cardiomyopathy, ICD PatientsArms18F-metaFluorobenzylguanidine, Rubidium-82
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. The prognostic value ofJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022
    Pooled it
  2. Article
  3. Machine learning-based prediction of conversion coefficients for I-123 metaiodobenzylguanidine heart-to-mediastinum ratio.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023
    Article
  4. Article
  5. Article
  6. Article
  7. The utility of heart-to-mediastinum ratio using a planar image created from IQ-SPECT with Iodine-123 meta-iodobenzylguanidine.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2021
    Article
  8. TheJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2021
    Article
  9. Article
  10. Article
  11. CardiacJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2021
    Article
  12. Article
  13. Review
  14. Phase dyssynchrony andJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2019
    Article
  15. Imaging cardiac innervation in amyloidosis.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2019
    Review
  16. IsAnnals of nuclear medicine · 2018
    Article
  17. Cross calibration ofAnnals of nuclear medicine · 2017
    Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kenichi NakajimaDepartment of Nuclear Medicine, Kanazawa University, 13-1 Takara-machi, Kanazawa, 920-8641 Japan.
Derk O VerschureDepartment of Nuclear Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Koichi OkudaDepartment of Physics, Kanazawa Medical University, Uchinada, Kahoku, Japan.
Hein J VerberneDepartment of Nuclear Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeMyocardial sympathetic imaging with

methodsThe planar HMR shows considerable variation due to differences in collimator design. These camera-collimator differences can be overcome by cross-calibration phantom experiments. The principles of these cross-calibration phantom experiments are summarized in this article.

resultsCalibration phantom experiments have been successfully performed in Japan and Europe. The benefit of these cross-calibration phantom experiments is that variation in the HMR between institutions is minimized including low-energy, low-medium-energy and medium-energy collimators. The use of myocardial

conclusionStandardization of myocardial

Indexed as

Calibration phantomCollimatorConversion coefficientHeart-to-mediastinum ratioQuantification

Identifiers

PMID28596948
PMCPMC5437131

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.